We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Consensus Estimate for earnings is pegged at $2.84 per share, indicating 2.5% growth from the year-ago quarter’s reported level. The consensus estimate for revenues is $16.6 billion, indicating 4.9% year-over-year growth.
Two consensus estimates for earnings per share in the second quarter of fiscal 2025 moved north in the past 60 days versus three southward revisions. The Zacks Consensus Estimate for its 2025 bottom line has increased marginally in the past 60 days.
Image Source: Zacks Investment Research
ACN’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, delivering an average surprise of 2.7%.
Our proven model does not conclusively predict an earnings beat for Accenture this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
Reinvention Partnerships to be ACN’s Key Driver in Q2
In the first quarter of fiscal 2025, Accenture witnessed its clients prioritizing large-scale transformations and considering the company to be their reinvention partner of choice. This strategy was fruitful in terms of bookings, as the company clocked it to have reached $18.7 billion, increasing from the year-ago quarter’s $18.4 billion. Bookings included 30 clients, with quarterly bookings surpassing $100 million.
Accenture’s emphasis on being the reinvention partner is a vital element of its strategy for achieving stronger growth. This reinvention partner strategy plays an important role in ACN’s growth plan. We anticipate the company to increase bookings to $23.1 billion in the second quarter of fiscal 2025. ACN will witness top-line growth from these large bookings throughout the year. Accenture’s relationships with its clients positions it to gain from higher discretionary spending.
ACN’s Stock Comparison With Peers
The stock has lost 8.3% in the past three months against the industry’s 12.5% fall and the Zacks S&P 500 composite’s 4.4% decline. Shares of its industry peers Realbotix Corp. (XBOTF - Free Report) and Stem, Inc. (STEM - Free Report) have risen 91.6% and 26.5% over the same period, respectively.
Three-Month Price Performance
Image Source: Zacks Investment Research
Accenture’s Investment Considerations
The GenAI market is expected to expand, witnessing a CAGR of 37.6% from 2025 to 2030. Accenture, being at the forefront to leverage GenAI, is anticipated to benefit from this market expansion. ACN’s partnerships with OpenAI, Sanctuary AI, and more have solidified the company’s position in the GenAI market. These collaborators provide access to AI models and solutions, allowing Accenture to develop solutions tailored to specific enterprise requirements.
ACN’s expertise in the GenAI domain drove $3 billion in GenAI-related bookings in fiscal 2024 and $1.2 billion in the first quarter of fiscal 2025. We anticipate improvements in bookings due to Accenture’s ability to capitalize on the GenAI market expansion. Meanwhile, Accenture has an asset-light business model with low CapEx and high FCF, facilitating frequent acquisitions. The company spent $6.6 billion across 46 acquisitions in fiscal 2024, demonstrating its inclination toward boosting performance by buying out companies.
Therefore, we can expect ACN to acquire more companies in the process of improving its AI services and expand in the market. In doing so, Accenture might face the risks of overpayment or making bad buyouts, mainly in the current turbulent AI market.
Hold on to ACN for Now
Accenture is well-positioned to leverage the GenAI market expansion, wherein partnerships that enable the company to improve its AI offerings will attract more clients. This strategy, coupled with ACN’s reinvention partnership strategy, will help it win more clients, thereby boosting the top line.
While acquisitions to boost AI offerings are common for ACN, they do not guarantee improved performance, and carry the risk of overpayment and bad investment choices. Hence, we recommend investors to remain patient and monitor Accenture’s ability to navigate within the AI market, which should be instrumental in making investment decisions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Accenture Pre-Q2 Earnings: Is the Stock a Portfolio Must-Have?
Accenture plc (ACN - Free Report) is set to report second-quarter fiscal 2025 results on March 20, before market open.
See Zacks Earnings Calendar to stay ahead of market-making news.
The Zacks Consensus Estimate for earnings is pegged at $2.84 per share, indicating 2.5% growth from the year-ago quarter’s reported level. The consensus estimate for revenues is $16.6 billion, indicating 4.9% year-over-year growth.
Two consensus estimates for earnings per share in the second quarter of fiscal 2025 moved north in the past 60 days versus three southward revisions. The Zacks Consensus Estimate for its 2025 bottom line has increased marginally in the past 60 days.
ACN’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, delivering an average surprise of 2.7%.
Accenture PLC Price, Consensus and EPS Surprise
Accenture PLC price-consensus-eps-surprise-chart | Accenture PLC Quote
Lower Chance of Q2 Earnings Beat for ACN
Our proven model does not conclusively predict an earnings beat for Accenture this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
ACN has an Earnings ESP of -2.84% and a Zacks Rank of 3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Reinvention Partnerships to be ACN’s Key Driver in Q2
In the first quarter of fiscal 2025, Accenture witnessed its clients prioritizing large-scale transformations and considering the company to be their reinvention partner of choice. This strategy was fruitful in terms of bookings, as the company clocked it to have reached $18.7 billion, increasing from the year-ago quarter’s $18.4 billion. Bookings included 30 clients, with quarterly bookings surpassing $100 million.
Accenture’s emphasis on being the reinvention partner is a vital element of its strategy for achieving stronger growth. This reinvention partner strategy plays an important role in ACN’s growth plan. We anticipate the company to increase bookings to $23.1 billion in the second quarter of fiscal 2025. ACN will witness top-line growth from these large bookings throughout the year. Accenture’s relationships with its clients positions it to gain from higher discretionary spending.
ACN’s Stock Comparison With Peers
The stock has lost 8.3% in the past three months against the industry’s 12.5% fall and the Zacks S&P 500 composite’s 4.4% decline. Shares of its industry peers Realbotix Corp. (XBOTF - Free Report) and Stem, Inc. (STEM - Free Report) have risen 91.6% and 26.5% over the same period, respectively.
Three-Month Price Performance
Accenture’s Investment Considerations
The GenAI market is expected to expand, witnessing a CAGR of 37.6% from 2025 to 2030. Accenture, being at the forefront to leverage GenAI, is anticipated to benefit from this market expansion. ACN’s partnerships with OpenAI, Sanctuary AI, and more have solidified the company’s position in the GenAI market. These collaborators provide access to AI models and solutions, allowing Accenture to develop solutions tailored to specific enterprise requirements.
ACN’s expertise in the GenAI domain drove $3 billion in GenAI-related bookings in fiscal 2024 and $1.2 billion in the first quarter of fiscal 2025. We anticipate improvements in bookings due to Accenture’s ability to capitalize on the GenAI market expansion.
Meanwhile, Accenture has an asset-light business model with low CapEx and high FCF, facilitating frequent acquisitions. The company spent $6.6 billion across 46 acquisitions in fiscal 2024, demonstrating its inclination toward boosting performance by buying out companies.
Therefore, we can expect ACN to acquire more companies in the process of improving its AI services and expand in the market. In doing so, Accenture might face the risks of overpayment or making bad buyouts, mainly in the current turbulent AI market.
Hold on to ACN for Now
Accenture is well-positioned to leverage the GenAI market expansion, wherein partnerships that enable the company to improve its AI offerings will attract more clients. This strategy, coupled with ACN’s reinvention partnership strategy, will help it win more clients, thereby boosting the top line.
While acquisitions to boost AI offerings are common for ACN, they do not guarantee improved performance, and carry the risk of overpayment and bad investment choices. Hence, we recommend investors to remain patient and monitor Accenture’s ability to navigate within the AI market, which should be instrumental in making investment decisions.